Desenvolvimento de novos complexos benzimidazólicos e polipiridil: síntese, caracterização e avaliação do potencial farmacológico e terapêutico

Abstract

Ruthenium (II) complexes have been under intense research due to their high acting in the different diseases, especially cardiovascular diseases and cancer. N-heterocyclic ligands, principally, compounds imidazole derivatives also have been considered promising systems based on their versatility and wide range of therapeutic applications like anticancer, bactericidal and antihypertensive. Additionally, coordination compounds containing NOx like ligands have to show great systems for treatment of cardiovascular diseases. Considering that, the main goal this work is synthetize new compounds with general formula [Ru(n-n)2L1L2] where (n-n) = 2,2’-bipiridina or 1,10 fenantrolina, L1 = Benzimidazol and L2 = Cl- , NO , Benzimidazol and NO+ aiming to obtain positive results for biological activity. The characterization was held using spectroscopic techniques agreeing with the proposed structures. The nitric oxide (NO0) releasing capability of the synthetized nitrosyl complexes were evaluated in different conditions. The spectroscopic monitoring of the application of electrical potential and under blue light irradiation (λmáx=460 nm) the results evidenced the suggesting NO0 releasing. In the spectrophotometric titration showed two inflection point for the complexes cis-[Ru(bpy)2(Bzim)(NO)]3+(I) e cis-[Ru(phen)2(Bzim)(NO)]3+(II) with conversion pH to 3.70 e 6.10(I); 2.26 e 6.40(II), respectively. In addition, the reactivity of nitrosyl complexes was studied with chemiluminescent sensor in two conditions, the first condition in HTFA 0,1 molL-1 and the second was using L- glutathione and wad showed NO release. In the vascular relaxation assays was demonstrating excellent hypotensive action for four compounds between the eight complexes synthetized. These results evidence the synthesis of the eight new candidates with potential application.